The use of biomarkers to determine which patients benefit from metastasis-directed radiation and which patients might benefit from the addition of hormonal therapy to metastasis-directed radiation I think is a really important question for the field. We are planning in the future additional biomarker analysis. I think that the jury is still out on what biomarkers might predict who would or would not benefit...
The use of biomarkers to determine which patients benefit from metastasis-directed radiation and which patients might benefit from the addition of hormonal therapy to metastasis-directed radiation I think is a really important question for the field. We are planning in the future additional biomarker analysis. I think that the jury is still out on what biomarkers might predict who would or would not benefit. Right now, I’m mostly looking at clinical characteristics as a key determinant. But I do think that the data suggests so far that most patients with low-volume oligometastatic prostate cancer may benefit from radiation in combination with hormonal therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
